W. Mohnike · G. Hör · H. R. Schelbert (Eds.)

Oncologic and Cardiologic PET/CT-Diagnosis

An Interdisciplinary Atlas and Manual

Wolfgang Mohnike · Gustav Hör
Heinrich R. Schelbert (Eds.)

Oncologic and Cardiologic PET/CT-Diagnosis

An Interdisciplinary Atlas and Manual

With DVD-ROM

With contributions by
Thomas Beyer · Konrad Mohnike · Stefan Käpplinger

With 909 Figures, 803 in Color and 24 Tables

Springer

Wolfgang Mohnike, MD
Professor
Diagnostisch Therapeutisches Zentrum
am Frankfurter Tor
Kadiner Strasse 23
10243 Berlin
Germany

Gustav Hör, MD
Professor
Klinik für Nuklearmedizin und Zentrum der Radiologie
Klinikum der J. W. Goethe-Universität
Theodor-Stern-Kai 7
60950 Frankfurt/Main
Germany

Heinrich R. Schelbert, MD, PhD
Gerorge V. Taplin Professor
Department of Molecular and Medical Pharmacology
David Greffen School of Medicine at UCLA
University of California at Los Angeles
650 Charles E. Young Drive South
Los Angeles, CA 90095
USA

ISBN 978-3-540-74090-2 e-ISBN 978-3-540-74091-9

DOI 10.1007 / 978-3-540-74091-9

Library of Congress Control Number: 2008923539

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitations, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag. Violations are liable for prosecution under the German Copyright Law.

The use of general descriptive names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publishers cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature.

Cover design: Frido Steinen-Broo, eStudio Calamar, Spain
Layout: PublishingServices Teichmann, 69256 Mauer, Germany

Printed on acid-free paper
9 8 7 6 5 4 3 2 1 0

springer.com

Foreword

Panels of experts in the USA und Europe agree that positron emission tomography (PET) is the imaging method that has been most rapidly accepted in the last decade.

In a review by Beyer and Townsend it was observed that in five years PET/CT has taken the place of coregistration. In institutions equipped with a combined PET/CT tomograph the advantages are increasingly recognised – particularly in pulmonology and thorax surgery.

The NNT (number needed to treat) is the standard according to which the number of patients to be successfully treated is measured. Careful diagnosis involving PET/CT with effective treatment can and must reduce the NNT.

The simultaneous preparation of fusion images in PET/CT shortens the examination time, spares the patient the time needed for two visits to the doctor and provides nuclear medical specialists and radiologists with anatometabolic images: Anatomy, (surrounding) structure, localisation and molecular biology expand the diagnostic framework. The current trend points towards PET/CT as a standard diagnostic method in oncology.

The dynamism of the development process is reflected already in the case studies shown here whose pictorial documentation is based on three generations of apparatus. The case studies document how PET/CT opens up new diagnostic options for the patient when the conventionally established examination methods fail. Decades of experience have taught us that such situations are by no means the exception, even today.

This book is intended to help answer the following questions: What are the strengths of PET/CT? What are its current limits, and what is its development potential?

On the enclosed DVD you will find a comprehensive overview of additional literature, the entire text in electronic form and several case studies which – when examined with the viewer – give an impression of the three dimensional nature of the studies.

Professor Dr. Gustav Hör
Specialist in Roentgenology and Radiology
Specialist in Nuclear Medicine

Acknowledgements

The part of this PET/CT Manual that deals with oncology is based on the German PET/CT Atlas by Mohnike and Hör, published in 2006, which has now been updated and expanded. At the same time, the important indication for PET(/CT) in cardiology receives the attention it urgently requires in the form of the important contribution by Prof. H. Schelbert. We thank him for his profound commitment and for taking on this task at short notice, as well as Prof. G. Hör for his European view of cardiological PET(/CT) examination options presented in his customary, esteemed manner.

The compilation and publication of an English-language manual was a real challenge for non-native speakers and could not have been achieved without the thorough and highly committed supervision of the journalist Ms S. Thürk M.A.

I am also grateful to my son, Konrad Mohnike, and to Dipl.-Phys. S. Käpplinger for their thorough checking of the manuscripts, as well as to Privatdozent Dr. T. Beyer for his careful revision of his contribution. Dr. U. Heilmann, Ms A. Hinze and Ms W. McHugh of Springer-Verlag were also of great assistance to us.

Thanks also go to Dr. T. Eberhard, diagnostic radiology specialist, C. Voelkel, radiologist, Prof. J. Schmidt and I. Volkova, nuclear medicine of the Diagnostic Therapeutic Centre (DTZ) in Berlin, my brother, Privatdozent Dr. Klaus Mohnike (Magdeburg University), and Dr. O. Blankenstein (paediatrician at Charité Berlin) for the working up of findings.

Special thanks go to Ms K. Stein of Siemens Medical Solutions and Dipl.-Math. Mr W. Lauermann for producing the DVD.

We would also like to thank Ms B. Engfer and Ms Y. Fobbe, medical radiological technicians, as well as all other staff, at the DTZ. Our thanks also go to Dipl.-Chem. Mr B. Zimontkowski and Mr J. Reinke, who were always ready to assist me with their help and advice.

We especially thank Messrs M. Reitermann, Dr. R. Radmanesh, N. Franke, R. Krämer and Dr. F. Anton of Siemens Medical Solutions for their fair and unbureaucratic assistance.

Finally, I would like to thank my wife, Bettina, for her constructive advice and patience throughout the project.

Professor Wolfgang Mohnike

Contents

1 Introduction – Positron Emission Tomography: Past and Present 1

1.1 Survey . . . 1
Physical and Biochemical Fundamentals . . . 2
PET in National and International Medical Care Systems . . . 2

1.2 Technological Variants and Developments . . . 4
Coincidence PET vs. Dedicated PET . . . 4
Differentiated PET Evaluation . . . 4
Radiotherapeutic Tools . . . 5
PET/CT – a New Key Technology . . . 5
Influence of PET/CT on PET . . . 5
Studies Dealing with the Cost Efficiency of PET Alone . . . 6
PET/CT or Comparison of Co-Registered Findings? . . . 6
"Standard" (CARE)-CT and PET/CT . . . 6
PET/MRI? . . . 6
American Joint Committee on Cancer . . . 7
PET Screening in Japan and Taiwan . . . 7

1.3 Increased FDG Uptake Due to Physiological and Technical Factors . . . 7

1.4 References . . . 8

2 Fundamentals

Thomas Beyer . . . 11

2.1 Preface . . . 11
Positron Emission Tomography (PET) . . . 11
Radioisotopes and PET Tracers . . . 12
Coincidence Measurement and Quantification . . . 13
PET Measurement Results and Reconstruction . . . 14
PET Scanners and Scintillation Detectors . . . 16

2.2 Combined PET/CT . . . 18
Retrospective Image Fusion . . . 18
The PET/CT Prototype . . . 18
CT-Based Attenuation Correction . . . 20
Commercialization of PET/CT . . . 21
New Technical Developments in PET/CT . . . 23
PET/CT Acquisition Protocols . . . 29
Sources of Errors and Optimization Options . . . 30
Radiation Protection Aspects . . . 37

2.3 Conclusion . . . 40

2.4 References . . . 40

3 Pneumology . . . 43

3.1 Bronchial Carcinoma (BC) . . . 43

3.2 Significance of FDG-PET in Diagnostic and Therapeutic Management . . . 44
Critical Evaluation of Diagnosis Management . . . 45

3.3 Guidelines for ^{18}F-FDG-PET Indications . . . 45

3.4 Technical and Biochemical Factors . . . 46
Is Coincidence PET Equivalent to Full-Ring PET? . . . 46
PET as Metabolism and Proliferation Marker . . . 46
Innovative Radiopharmacy . . . 46

3.5 Special PET Indications . . . 47
False-Negative PET . . . 47
False-Positive PET . . . 47
How Useful Is Integrated PET/CT? . . . 48

3.6 SCLC (Small-Cell Lung Cancer) . . . 48

3.7 Pleural Processes . . . 48
Malignant Pleural Tumours (Mesothelioma) . . . 49
Imaging Methods . . . 49

3.8 Case Studies . . . 50
Patient 1 Scar Carcinoma of the Lung . . . 50
Patient 2 Pneumonia . . . 52
Patient 3 Lymph Node Metastases of a Squamous Cell Carcinoma . . . 54
Patient 4 Metastasized Bronchial Carcinoma . . . 56
Patient 5 Round Focus in the Lung . . . 58
Patient 6 Metastasized Bronchial Carcinoma . . . 60
Patient 7 Metastasized Adenocarcinoma in the Left Lower Lobe of the Lung . . . 61
Patient 8 Downstaging of a Squamous Cell Carcinoma of the Lung . . . 62
Patient 9 Preoperative Staging of a Bronchial Carcinoma . . . 64
Patient 10 Pleural Carcinosis after Pneumectomy . . . 66
Patient 11 Recurrence of a Brain Metastasis . . . 69
Patient 12 Pleural Mesothelioma . . . 71
Patient 13 Prevention of Non-Curative Thoracic Surgery . . . 73
Patient 14 Upstaging of a Bronchial Carcinoma . . . 76
Patient 15 Bilateral Metastases of an NSCLC in the Suprarenal Glands . . . 79

3.9 References . . . 82

4 Gastroenterology 85

4.1 Introduction 86
Molecular Strategy 87
Metabolic Influencing Factors 88
PET Screening? 88
Incidentally Detected Lesions (IDL) 88

4.2 Oesophageal Carcinoma 88
PET in Diagnosis Management of Oesophageal Carcinoma 88

4.3 Gastric Carcinoma 90
MALT Lymphomas 90

4.4 Colorectal Carcinomas 90
Treatment 91
Status of PET 91
PET/CT as the Optimum 93
PET Indications 93
Limitations of PET 94
Artefacts 94
FDG-PET 94
Alternative and Adjuvant Markers 94
Synopsis 95

4.5 Liver and Biliary Tract Carcinomas 95

4.6 Gastrointestina Stromal Tumours 95

4.7 Pancreas Carcinomas 96
Imaging 96
Curative Treatment 97
New Gene-Based Treatment Strategies 97
Indications 97
DGN Classes, Consequences 97
Impact of SUVs on Survival Time 97
False-Negative/-Positive PET Findings 97
Pancreas NETs (Neuroendocrine Tumours) . . . 98

4.8 Neuroendocrine Tumours (NETs) of the Gastrointestinal Tract 98
Carcinoids 98
Conventional Diagnostics 98
NET Spectrum 99
Biochemistry 99
High Secretors 99
Low (Non-)Secretors 99
Limitations of PET 99

4.9 Case Studies 100
Patient 1 Oesophageal Carcinoma 100
Patient 2 Lymph Node Metastasis of an Oesophageal Carcinoma 103
Patient 3 Downstaging of an Oesophageal Carcinoma 105
Patient 4 Carcinoma of the Head of the Pancreas 107
Patient 5 Metastasized Carcinoma of the Head of the Pancreas 110
Patient 6 Carcinoma of the Body of the Pancreas 112
Patient 7 Hepatocellular Carcinoma with Multiple Metastases 114
Patient 8 Gastric Carcinoma 117
Patient 9 Leiomyoma of the Stomach 118
Patient 10 Follow-Up of an Adenocarcinoma of the Stomach 121
Patient 11 Staging of an Adenocarcinoma of the Stomach 123
Patient 12 Staging of a Carcinoma of the Corpus of the Stomach 124
Patient 13 Lymph Node Metastasis from Gastric Carcinoma 126
Patient 14 Extended Metastatic Spread to the Liver from Adenocarcinoma of the Stomach 128
Patient 15 Caecum Carcinoma 130
Patient 16 Carcinoma of the Colon Ascendens . 132
Patient 17 T1 Carcinoma of the Colon 134
Patient 18 Adenocarcinoma of the Sigmoid Colon 136
Patient 19 Liver Metastasis of a Colon Carcinoma 138
Patient 20 Lymphoma Conglomerate Following Colon Carcinoma 140
Patient 21 Lung Metastasis Following Colon Carcinoma 142
Patient 22 Pulmonary, Hepatic and Lymphogenic Metastatic Spread Following Sigmoid Carcinoma 144
Patient 23 Metastasized Sigmoid Carcinoma . . 146
Patient 24 Peritoneal Carcinosis and Ascites Following Sigmoid Carcinoma 148
Patient 25 Lung Metastasis Following Sigmoid Carcinoma 150
Patient 26 Liver Metastasis Following Sigmoid Carcinoma 153
Patient 27 Lymph Node Metastasis Following Sigmoid Carcinoma 156
Patient 28 Metastatic Spread to the Liver Following Rectal Carcinoma 158
Patient 29 Liver and Lung Metastases Following Rectal Carcinoma 160
Patient 30 Rectal Carcinoma with Lymph Node Metastases 163
Patient 31 Suprarenal and Lung Metastases Following Rectal Carcinoma 166
Patient 32 Lung and Bone Metastases Following Rectal Carcinoma 168
Patient 33 Suprarenal Metastasis of a Rectal Carcinoma 169
Patient 34 Restaging of a Rectal Carcinoma . . 172
Patient 35 Suprarenal and Lung Metastases Associated with Rectal Carcinoma . 174
Patient 36 Restaging of a Rectal Carcinoma . . 176
Patient 37 Local Recurrence and Liver Metastases of a Rectal Carcinoma . . 178
Patient 38 Extended Metastatic Spread of a Mesenterial Conglomerate Tumour . 181
Patient 39 GIST Tumour with Liver Involvement 183
Patient 40 Malignoma in the Left Epigastric Region 184

Patient 41 GIST, Metastasis at the Greater Curvature of the Stomach . . 186
Patient 42 Tumour Recurrence with Status Post GIST of the Stomach . . . 187
Patient 43 Therapy Response Follow-Up Examination Post GIST Resection . . 189
Patient 44 Therapy Follow-Up in the Case of GIST 193

4.10 References 200

5 Gynaecology 205

5.1 Introduction 206
The Importance of Nuclear Medical Methods 206

5.2 Breast Cancers 206
Mammography 207
Tumour Markers 208
CT and MRI 208
^{18}F-Fluoride 209
SPECT 209
Sentinel Node Scintigraphy (SNS) 209
Positron Emission Tomography 209
Preoperative Axillary Staging 210
Extra-Axillary Metastases 211
Treatment Monitoring 211
Potentials and Limitations of PET 211
Special Neuro-Oncological Problems/Pitfalls . . 212
PET Screening? 212
Risk Stratification 212
PET/CT 212
Assessment of the Bone Status 212
^{18}F-Fluoride PET 212
Diagnostic Imaging of the Breast: Indications . 212

5.3 Ovarian Cancer 213
Tumour Types 213
Conventional Diagnostics 213
PET 213

5.4 Peritoneal Cancer (PC) 215

5.5 Cervical Cancer 215
PET Diagnostics 215

5.6 Case Studies 216
Patient 1 Lymph Node Metastasis with Status Post Carcinoma of the Right Breast and Ovarian Carcinoma on Both Sides 216
Patient 2 Inflammatory Breast Cancer 218
Patient 3 Breast Cancer with Osseous Metastases 220
Patient 4 Preoperative Staging of a Breast Cancer 222
Patient 5 Restaging of a Breast Cancer 224
Patient 6 Restaging of a Breast Cancer 226
Patient 7 Confirmation of the Diagnosis "Breast Cancer" 228
Patient 8 Psammoma 230
Patient 9 Ovarian Cancer 232
Patient 10 Restaging of an Ovarian Cancer . . . 234
Patient 11 Therapy Response of a Metastasized Ovarian Cancer 236
Patient 12 Metastasized Cervical Cancer 238
Patient 13 Bone Metastasis of a Corpus Uteri Cancer 240
Patient 14 Trophoblastic Tumour 242
Patient 15 Malignant Ovarian Cyst 244
Patient 16 Peritoneal Carcinosis Due to Ovarian Cancer 245
Patient 17 Metastasized Endometrial Carcinoma 248
Patient 18 Exclusion of Metastatic Spread of an Endometrial Carcinoma 250
Patient 19 Therapy Control in Case of Ovarian Carcinoma 252
Patient 20 Lymph Node and Bone Metastases in Case of Ovarian Carcinoma 254
Patient 21 Local Recurrence of Breast Cancer . 256
Patient 22 Restaging of a Breast Cancer after Chemotherapy 259
Patient 23 Restaging of a Breast Cancer after Rise in Tumour Marker Level 261
Patient 24 Primary Staging of a Breast Cancer . 262
Patient 25 Restaging of a Breast Cancer after Reduction in Tumour Marker Level . 264
Patient 26 Pre-Therapeutic Staging of a Breast Cance 267
Patient 27 Restaging of a Metastasized Breast Cancer 269
Patient 28 Detection of Metastases by PET/CT with Negative Conventional Imaging 271
Patient 29 Therapy Control of a Metastasized Breast Cancer 275
Patient 30 Therapy Control of a Metastasized Breast Cancer 276
Patient 31 Evaluation of Radiotherapy Response in Case of Metastasized Breast Cancer 279
Patient 32 Restaging of a Breast Cancer 283
Patient 33 Restaging of a Breast Cancer Revealing a Fracture Risk in the C6 Vertebral Body 285
Patient 34 Restaging of a Breast Cancer with PET/CT Providing Much More Detailed Information 287
Patient 35 Pleural Carcinosis in a Patient with Breast Cancer 290
Patient 36 Lung Metastases of a Breast Cancer . 292
Patient 37 Bone Metastases of a Breast Cancer . 294
Patient 38 Male Patient with Metastasized Breast Cancer 296

5.7 References 298

6 Urology 303

6.1 **Introduction** 303

6.2 **Renal Malignancies** 304
Introduction 304
Diagnostics 304

6.3 **Adrenal Tumours** 305
Imaging Diagnostics 305

6.4 **Bladder Carcinoma** 305
Status of PET 306

6.5 **Prostate Carcinoma** 306
Introduction 306
Diagnostics 306
Treatment 309
Status of Individual Imaging Methods 309

6.6 **Germ Cell Tumours** 313
Introduction 313
PET Study Situation 314

6.7 **Penis Carcinoma** 315

6.8 **Case Studies** 316
Patient 1 Malignoma of the Base of the Bladder . 316
Patient 2 Malignoma of the Posterior Wall of the Bladder 318
Patient 3 Metastasis in the Suprarenal Gland on the Left Side 320
Patient 4 Metastasis in the Suprarenal Gland on the Right Side 322
Patient 5 Metastasized Renal Cell Carcinoma . 325
Patient 6 Restaging after Chemotherapy 327
Patient 7 Restaging after Tumour Nephrectomy 330
Patient 8 Recurrence after Tumour Nephrectomy 332
Patient 9 Metastasized Prostate Carcinoma . . 334
Patient 10 Metastasized Prostate Carcinoma . . 336
Patient 11 Restaging of a Prostate Carcinoma . 338
Patient 12 Lymph Node Metastasis of a Prostate Carcinoma 340
Patient 13 First Diagnosis of a Prostate Carcinoma 342
Patient 14 Restaging of a Prostate Carcinoma . 343
Patient 15 Restaging of a Prostate Carcinoma . 345
Patient 16 Therapy Control for Metastatized Prostate Carcinoma 347
Patient 17 Staging of a Prostate Carcinoma . . . 349
Patient 18 Local Recurrence of a Prostate Carcinoma 351
Patient 19 Lymph Node Metastasis of a Prostate Carcinoma 352
Patient 20 Lymph Node Metastases of a Prostate Carcinoma 353
Patient 21 First Diagnosis of a Prostate Carcinoma 354
Patient 22 Prostatitis 355
Patient 23 Prostatitis 356
Patient 24 Prostatitis 357
Patient 25 Restaging of a Prostate Carcinoma . 359
Patient 26 First Diagnosis of a Prostate Carcinoma 361
Patient 27 Response Evaluation of a Prostate Carcinoma 362

6.9 **References** 363

7 Head and Neck Region 369

7.1 **Head and Neck Tumours** 369
^{18}F-FDG-PET 371
FDG-PET Pitfalls 373
PET Indications 373

7.2 **Thyroid Carcinomas** 374
^{18}F-FDG-PET 375

7.3 **Case Studies** 378
Patient 1 CUP Tumour 378
Patient 2 Tumour Recurrence of an Atypical Laryngeal Carcinoid . . 380
Patient 3 Restaging of an Oropharyngeal Carcinoma 381
Patient 4 Hypopharyngeal Carcinoma 384
Patient 5 Restaging after Multiple Carcinoma 386
Patient 6 Auricle Carcinoma 388
Patient 7 Tonsillar and Laryngeal Carcinoma and Carcinoma of the Base of the Tongue 390
Patient 8 Recurrence of a Squamous Cell Carcinoma of the Tongue 392
Patient 9 Tonsillar Carcinoma 394
Patient 10 Restaging of a Small-Cell Carcinoma of the Left Principal Nasal Cavity . . 396
Patient 11 Recurrence of a Vocal Cord Carcinoma. 400
Patient 12 Cerebral Metastatic Spread of a Bronchial Carcinoma 402
Patient 13 Cystadenocarcinoma of the Lacrimal Sac 405
Patient 14 Alzheimer's Disease 406
Patient 15 Oligodendroglioma on the Left Side 408
Patient 16 Low-Malignancy Brain Tumour on the Left Side 410
Patient 17 Hypophyseal Metastasis 413

7.4 **References** 415

8 Dermatology 419

8.1 **Malignant Melanoma (MM)** 419
Introduction 419
Significance of PET 421
Pitfalls 421
PET Indications 421

8.2 **Case Studies** 422
Patient 1 Malignant Melanoma of the Right Thigh 422
Patient 2 Recurrent Melanoma 424

Patient 3 Metastasized Melanoma 426
Patient 4 Choroidal Melanoma 427
Patient 5 Metastasized Amelanotic Melanoma 428

8.3 References 433

9 Lymphomas 435

9.1 Introduction 435

9.2 Diagnosis 436
Imaging Methods 436
FDG-PET 437
Response Evaluation 437
Comparison of FDG-PET, ^{67}Ga and CT 438
Autologous Stem Cell Therapy 438
PET/CT Restaging 438
Artefacts 439
Other Problems 439
PET Indications 439

9.3 Case Studies 440
Patient 1 Follicular Non-Hodgkin's Lymphoma 440
Patient 2 Metastasized Non-Hodgkin's Lymphoma 442
Patient 3 B-Cell Lymphoma in the Hypopharynx 444
Patient 4 B-Cell Lymphoma 446
Patient 5 Lymphogranulomatosis, Nodular Sclerosis 448
Patient 6 T-Cell Lymphoma of the Cervical Lymph Tract 449
Patient 7 B-Cell Lymphoma 451
Patient 8 Restaging of Hodgkin's Disease . . . 454
Patient 9 Recurrent Hodgkin's Lymphomas . . 459
Patient 10 Chronic Lymphatic Leukaemia . . . 461
Patient 11 Restaging of the Multiple Myeloma . 461

9.4 References 463

10 Oncological Orthopaedics 465

10.1 Introduction 465

10.2 Significance of PET 465
PET Tracers 466
PET Indications 466

10.3 Case Studies 467
Patient 1 Sweat Gland Carcinoma 467
Patient 2 Haemangioendothelioma 470
Patient 3 Chondrosarcoma 473
Patient 4 Medullary Osteosarcoma 476
Patient 5 Clear Cell Sarcoma 478
Patient 6 Rhabdomyosarcoma 480
Patient 7 Rhabdomyosarcoma of the Left Thigh 482
Patient 8 Embryonal Rhabdomyosarcoma . . . 484

10.4 References 486

11 Paediatric Oncology 487

11.1 Introduction 487
Changes in the Range of Clinical Indications . . 488

11.2 Lymphomas in Childhood 488
Staging, Restaging, Prognosis and Therapy Control 488

11.3 Oncological Orthopaedics in Childhood 488

11.4 Neuroblastomas 488

11.5 Malignant Melanomas 488

11.6 Nesidioblastosis (Congenital Hyperinsulinism) 489

11.7 Case Studies 490
Patient 1 Status Post Osteogenous Sarcoma . . 490
Patient 2 Status Post Mastitis 491
Patient 3 Embryonal Rhabdomyosarcoma . . . 492
Patient 4 Focal Congenital Hyperinsulinism . 494
Patient 5 Focal Congenital Hyperinsulinism . 496
Patient 6 Focal Congenital Hyperinsulinism . 498
Patient 7 Diffuse Congenital Hyperinsulinism 500
Patient 8 Focal Congenital Hyperinsulinism . 502
Patient 9 Focal Congenital Hyperinsulinism . 504
Patient 10 Focal Congenital Hyperinsulinism . 506
Patient 11 Langerhans Cell Histiocytosis 508
Patient 12 Langerhans Cell Histiocytosis, Staging and Restaging 510

11.8 References 514

12 CUP Tumours 515
(Cancer of Unknown Primary)

12.1 Introduction 515

12.2 Significance of PET 516
Cancer of Unknown Primary: Indication for PET/CT? 516
Studies Available 516
Artefacts, Pitfalls and Metabolic Heterogeneity . 516

12.3 Case Studies 517
Patient 1 Carcinoma of the Base of the Tongue 517
Patient 2 Carcinoma of the Base of the Tongue 518
Patient 3 Oropharyngeal Carcinoma 520
Patient 4 Cholangiocarcinoma 523
Patient 5 Pancreatic Carcinoma 526
Patient 6 Carcinoma of the Head of the Pancreas 528
Patient 7 Mamma Carcinoma 530
Patient 8 CUP Tumour 533
Patient 9 Mamma Carcinoma 536
Patient 10 Carcinoma of the Base of the Tongue 538
Patient 11 Bronchial Carcinoma 540
Patient 12 Bronchial Carcinoma 542

12.4 References 544

13 Pitfalls 545

13.1 Testicular Carcinoma and Other Primary Tumours 546
Universal Organ Spectrum of SPT 546

13.2 Physiological Accumulation of FDG 547

13.3 False Positive FDG Accumulations in the Oncological Sense 547

13.4 Artefacts Due to Technical Factors 547

13.5 False Negative PET Findings 547

13.6 Case Studies Secondary Tumours 548
Patient 1 Inflammatory Carcinoma of the Breast and Papillary Carcinoma of the Inner Genital Tract 548
Patient 2 Carcinoma in Situ with Osteoplastic Metastases 10 years later 551
Patient 3 Recurrence of a Sigmoid Carcinoma, Compression of the Left Ureter . . . 554
Patient 4 Cervical Carcinoma and Rectal Carcinoma 556
Patient 5 Mamma Carcinoma and Colon Carcinoma 558
Patient 6 Mamma Carcinoma and Sigmoid Carcinoma 560
Patient 7 Thymoma 561
Patient 8 Prostate Carcinoma and Colon Carcinoma 564
Patient 9 Renal Cell and Prostate Carcinoma . 566
Patient 10 Prostate Carcinoma and Colon Carcinoma 568
Patient 11 Carcinoma in Situ of the Rectum and Bronchial Carcinoma 570
Patient 12 Non-Hodgkin's Lymphoma and Bronchial Carcinoma 574
Patient 13 Mamma Carcinoma and Bronchial Carcinoma 577
Patient 14 Coecum, Bronchial and Renal Carcinoma 579
Patient 15 Mamma, Cervical and Rectal Carcinoma 583
Patient 16 Parotid and Colon Carcinoma 586

13.7 Case Studies Physiologically Increased Uptake 589
Patient 17–21 589

13.8 Case Studies Non-Oncological Increased Uptake of Inflammatory Genesis 593
Patient 22–31 593

13.9 Case Studies Artefacts 611
Patient 32–39 611

13.10 References 622

14 Radiotherapeutic Aspects 625

14.1 Introduction 625

14.2 PET-Assisted Radiotherapy Planning 625

14.3 Advantages of PET/CT Integration 626

14.4 Fundamentals Governing the Use of PET/CT Data for Radiotherapy – Bits and Bytes and DICOM . . . 626

14.5 Case Studies 630
Patient 1 Prostate Cancer 630
Patient 2 Oropharyngeal Cancer 632
Patient 3 Breast Cancer 634
Patient 4 Prostate Cancer 636
Patient 5 Squamous Cell Carcinoma of the Oral Cavity 638
Patient 6 Bronchial Cancer 640

14.6 References 643

15 Nuclear Cardiology 645
– the Situation in Europe

15.1 Introduction 645
Development of Nuclear Cardiology and the Present State 645
Molecular Cardiac Imaging 647
Fusion Imaging 649
SPECT and SPECT/CT 650
MRI and PET/MRI 652

15.2 Cardiac PET/CT 652
Coronary Sclerosis 652
Diabetes Mellitus and Coronary Sclerosis 654
Plaque Imaging 655
Perfusion 656
Vitality 657
Radiation Exposure and Contrast Medium Safety 657
Artefacts 658
Invasive Diagnostics, Treatment and Treatment Monitoring 658
Prevention 661
Remarks on the Catalogue for Further Training for the Specialization in Nuclear Medicine 661

15.3 Case Studies 663
Patient 1 Mild CHD 663
Patient 2 Status Post Revascularization 666
Patient 3 Status Post Anterior Infarction and Sextuple Bypass 668
Patient 4 Surprise Finding of Stem Stenosis 672

15.4 Reference 676

16 Cardiac PET and PET/CT *687*
– the Situation in the USA

16.1 Introduction *687*
16.2 Coronary Artery Disease *687*
Imaging with PET *688*
Accuracy of PET and PET/CT Stress-Rest Myocardial Perfusion Imaging *693*
Advantages of Myocardial Perfusion Imaging with PET *696*
Hybrid PET/CT Myocardial Perfusion Imaging in Coronary Artery Disease *697*
16.3 Myocardial Viability *698*
Concepts and Pathophysiology *699*
Assessment of Myocardial Viability *699*
Imaging of Myocardial Perfusion and Metabolism *701*
Clinical Implications of Perfusion Metabolism Imaging *705*
PET/CT vs. Stand-Alone PET *707*
Clinical Indications of Perfusion Metabolism Imaging *708*
16.4 Vascular Inflammation and Atherosclerosis . . *709*
16.4.1 Large Vessel Vasculitis *709*
16.4.2 Atherosclerosis and Plaque Imaging *711*
16.5 Future Developments *714*
16.6 References *714*

17 Future Trends: Molecular PET *721*

17.1 Technical Potential and Software Optimization *721*
17.2 Molecular PET *722*
Tumour Vitality and Glucose Transporters (GLUT) *722*
Therapeutic and Diagnostic Potential *722*
17.3 Final Remark *723*
17.4 References *724*

Subject Index *727*